What is SonoVascular?
SonoVascular is a clinical-stage medical device company dedicated to developing an advanced ultrasound-based thrombectomy system. This innovative platform is engineered to treat both venous and arterial blood clots. The company's proprietary catheter technology integrates therapeutic ultrasound, microbubbles, and targeted drug delivery mechanisms. This combination aims to effectively clear clot burden while meticulously preserving the health and integrity of the patient's vessels, addressing a critical unmet need in vascular care.
How much funding has SonoVascular raised?
SonoVascular has raised a total of $6M across 1 funding round:
Series A
$6M
Series A (2026): $6M with participation from Harbright Ventures
Key Investors in SonoVascular
Harbright Ventures
Harbright Ventures is an investment firm focused on fueling the growth of innovative companies that create positive impacts on people and the planet. They provide capital resources, strategic connections, and expert guidance to early-stage businesses across various sectors, including medical technology, industrial technology, clean/green technology, and B2B SaaS.
What's next for SonoVascular?
The substantial enterprise-level funding positions SonoVascular for accelerated growth and the advancement of its thrombectomy system through critical clinical trials and regulatory pathways. This strategic investment is expected to fuel further research and development, enhance manufacturing capabilities, and support market penetration efforts. The company's focus on preserving vessel health while efficiently clearing clots suggests a trajectory towards becoming a leader in minimally invasive vascular treatments, potentially reshaping current standards of care.
See full SonoVascular company page
